Emcure Pharmaceuticals IPO opens for subscription on July 3, 2024. Develops and manufactures various pharmaceutical products across major therapeutic areas.
Prominent shareholders include Satish Mehta and Bain Capital. From March 2023 to March 2024, Emcure's profit decreased by 6.1%, while sales rose by 11.33%
IPO subscription: July 3-5, 2024. Anchor investor allocation on July 2. Allotment finalization on July 8. Listing on BSE & NSE on July 10.
Price band: ₹960 to ₹1,108 per share. Minimum lot size: 14 shares. The issue comprises a fresh issue and an offer for sale totaling ₹1,952.03 crore.
Funds to repay borrowings and for general corporate purposes. Emcure aims to utilize IPO proceeds to enhance financial flexibility and corporate growth.
50% for QIBs, 15% for NIIs, 35% for retail investors. Employees get a discount of ₹90 per share, with up to 108,900 shares reserved for them.